Combined treatment with bexarotene and rosuvastatin reduces angiotensin‐II‐induced abdominal aortic aneurysm in apoE−/− mice and angiogenesis
2015
Background and Purpose
Abdominal aortic aneurysm (AAA) is a degenerative vascular disease associated with angiogenesis. Bexarotene is a retinoid X receptor (RXR) ligand with anti-angiogenic activity. Statins also exert anti-angiogenic activity and activate PPARs. Because RXR ligands form permissive heterodimers with PPARs and a single anti-angiogenic drug may not be sufficient to combat the wide array of angiogenic factors produced during AAA, we evaluated the effect of combined low doses of bexarotene and rosuvastatin in a mouse model of AAA.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
67
References
18
Citations
NaN
KQI